Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension

Détails

ID Serval
serval:BIB_D9D82C821BCE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension
Périodique
British Journal of Clinical Pharmacology
Auteur(s)
Brunner  H. R., Gavras H., Waeber B., Turini  G. A., McKinstry  D. N., Vukovich  R. A., Gavras I.
ISSN
0306-5251
Statut éditorial
Publié
Date de publication
1979
Peer-reviewed
Oui
Volume
7 Suppl 2
Pages
205S-211S
Langue
anglais
Notes
Journal Article
Résumé
1 Captopril (SQ14,225), an orally active inhibitor of angiotensin-converting enzyme, was administered to nine patients with essential hypertension. Plasma renin activity (PRA) was low in four, 'normal' in three and high in two patients. 2 In the hospital, captopril alone induced a significant drop in BP from 165 +/- 6/106 +/- 2 to 140 +/- 5/90 +/- 1 mmHb (P less than 0.001). PRA increased concomitantly (P less than 0.05), whereas plasma-converting enzyme activity (P less than 0.005) and plasma aldosterone (P less than 0.05) were reduced. 3 Six patients underwent chronic ambulatory therapy with captopril for a mean of 16 +/- 3 weeks. After discharge from the hospital, BP remained normalized but in five out of six patients this required additional diuretic therapy. 4 The results suggest that captopril alone or combined with diuretic therapy provides a new, efficient and well tolerated tool to treat patients with essential hypertension independently of their PRA level. It may turn out to be more effective in lowering BP than beta-adrenoceptor-blocking agents.
Mots-clé
AdultAldosterone/blood*Angiotensin-Converting Enzyme InhibitorsBlood Pressure/drug effectsFemaleHumansHypertension/*drug therapyMaleMiddle AgedProline/*analogs & derivatives/therapeutic useRenin/blood
Pubmed
Web of science
Création de la notice
06/03/2009 12:00
Dernière modification de la notice
20/08/2019 15:59
Données d'usage